Epoxide Hydrolase Activator

PAL-4 (compound 4) is a potent, selective and reversible Lysophospholipase-like 1 (LYPLAL1) activator with EC₅₀ value of 0.39 μM and 0.49 μM for mice LYPLAL1 and huamn LYPLAL1, respectively. PAL-4 can be used for researching metabolic disorders.

Glucoerucin potassium is an orally active PTP1B non-competitive allosteric inhibitor (IC₅₀ = 6.07 μM) and H₂S donor that can be isolated and extracted from Eruca sativa. Glucoerucin potassium upregulates the Nrf2 pathway and promotes irisin/UCP1-mediated adipose tissue browning through conversion to erucin or acting as a sustained-release H₂S donor, thereby regulating metabolic and cardiovascular functions. Glucoerucin potassium also exerts anticancer effects by upregulating epoxide hydrolase and through non-competitive allosteric inhibition of PTP1B. Glucoerucin potassium can be used in research on obesity, cancer, type 2 diabetes, and cardiovascular and cerebrovascular diseases.

Glucoerucin potassium is an orally active PTP1B non-competitive allosteric inhibitor (IC₅₀ = 6.07 μM) and H₂S donor that can be isolated and extracted from Eruca sativa. Glucoerucin potassium upregulates the Nrf2 pathway and promotes irisin/UCP1-mediated adipose tissue browning through conversion to erucin or acting as a sustained-release H₂S donor, thereby regulating metabolic and cardiovascular functions. Glucoerucin potassium also exerts anticancer effects by upregulating epoxide hydrolase and through non-competitive allosteric inhibition of PTP1B. Glucoerucin potassium can be used in research on obesity, cancer, type 2 diabetes, and cardiovascular and cerebrovascular diseases.